Phaseline

Targets › HTR1D

HTR1D (5-hydroxytryptamine receptor 1D): drug programs, companies and trials

7 programs from 5 companies in 12 trials: 5 Phase 1, 3 Phase 2, 2 Phase 3, 2 Phase 4; Psychiatry, Neurology, Other; next expected readout Dec 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. (UniProt, P28221)

Open in Phaseline: the race on HTR1D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ZogenixFenfluramine
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile SpasmNov 2027
UCB BIOSCIENCESfenfluramine hydrochloride
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3Rett SyndromeFeb 2029
University Hospital, Basel, SwitzerlandLysergic Acid Diethylamide Tartrate (LSD)
Serotonin receptor agonist (5-HT1B/1D/7)
HTR1B, HTR1DPhase 2Palliative Care; Cluster HeadacheSep 2027
Yale UniversityDimethyltryptamine (DMT)
Serotonin 5-HT receptor agonist; endogenous psychedelic compound
HTR1A, HTR1B, HTR1D, HTR2APhase 1Major Depressive Disorder; Alcohol Use Disorder (AUD)Dec 2026
TechnophageEletriptan Hydrobromide
Serotonin 1f (5-HT1f) receptor agonist; Serotonin 1b (5-HT1b) receptor agonist; Serotonin 1d (5-HT1d) receptor agonist
HTR1F, HTR1B, HTR1DPhase 1Acute Spinal Cord Injury (SCI)Dec 2026
University Hospital, Basel, SwitzerlandDMT
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–
University Hospital, Basel, SwitzerlandLSD
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–

Conditions

Healthy (2) Rett Syndrome (1) Palliative Care (1) Cluster Headache (1) CDKL5 Deficiency Disorder (1) Dravet Syndrome (DS) (1) Dravet Syndrome (1) Infantile Spasm (1) Major Depressive Disorder (1) Alcohol Use Disorder (AUD) (1) Acute Spinal Cord Injury (SCI) (1)

Modalities

small molecule (7)

Companies

University Hospital, Basel, Switzerland (3) UCB BIOSCIENCES (1) Zogenix (1) Yale University (1) Technophage (1)

Related targets

HTR1B (5) HTR1A (3) HTR2C (2) SIGMAR1 (2) HTR5A (2) HTR7 (2) HTR2A (1) HTR1F (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.